Acurx Pharmaceuticals Inc (ACXP) Stock Price, Quote & News

Company Profile

Acurx Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, develops antibiotics to treat bacterial infections in the United States. The company's lead antibiotic candidate is ibezapolstat, a novel mechanism of action that targets the polymerase IIIC enzyme that is in Phase 2b clinical trial to treat patients with clostridium difficile infections. It also develops ACX-375C, a potential oral and parenteral treatment targeting gram-positive bacteria, including methicillin-resistant st...

Industry: Biotechnology

Sector: Healthcare

Phone: 917 533 1469

Website: www.acurxpharma.com

Address:

259 Liberty Avenue, Staten Island, United States

NotBornYesterday Feb. 23 at 4:07 PM

$ACXP My stink bid got hit at the open this morning. I’m long a small amount. Fundamental risks are still VERY high, but its safe to say sentiment is rock bottom and valuation is cheap enough to warrant a punt on the long side in front of Pumpalooski’s upcoming conference call. God forbid they actually get some help from the govt. This is not for everyone. Don‘t bet the farm. Zero is still possible if not probable.

0 · Reply

PUMPLESTILTSKIN Feb. 21 at 12:07 AM

$ACXP two weeks and down $0.38. right on track for $0.99 by mid-late March. I'm wondering if Luci will be able to fit another dilution in before he has to do another reverse split. He's only got a few weeks to do so.

0 · Reply

AZOZ Feb. 20 at 2:39 PM

$ACXP On watch for possible reversal soon!

2 · Reply

RenDragon Feb. 19 at 6:44 PM

$ACXP so soon we’ll hear from the gravy-man about how the bitcoin investment went.

0 · Reply

RegulatoryPro Feb. 18 at 4:26 PM

$ACXP Acurx Pharmaceuticals focuses on antibiotics with unmet need. Clinical validation is required to unlock valuation. Development timelines are long.

0 · Reply

GoodNewsBull Feb. 18 at 1:43 PM

$OKST so 1st off you MAGA crazy fool Im not "your dude" 2nd You bought $DJT over $90 & it went to $9 and you didnt sell a sahre, 90% of your stream for the past 6 years are losing trades & 100% of your stream is you talking like a wackado about "Dems" Truth is youre clearly not well, you're in love with another Man wjho has screwed you out of your money, you make fun of Kamala who has done more in her life the yopu ever will, She was VP of these United States, you sit in your undewear, eat Chick Fil A & have never kissed a girl So its not "Bycell its Incell As for "getting a life" everyone on ST can read your stream & there is no way some MAGA fool who bought $DJT over $90 should even be talking right now $DIS $ACXP

0 · Reply

Bonso99 Feb. 16 at 5:34 PM

$ACXP🫡🫡🫡🫡🫡 https://www.linkedin.com/posts/david-luci-acurx_presidentsday-leadership-innovation-activity-7429162868790444032-BC5o?utm_source=li_share&utm_content=feedcontent&utm_medium=g_mb_web&utm_campaign=copy

0 · Reply

tomcat79 Feb. 16 at 3:13 PM

$ACXP Acurx Pharmaceuticals to Discuss Full Year and Fourth Quarter 2025 Financial Results on March 13, 2026 Conference Call and Provide Business Update STATEN ISLAND, N.Y., Feb. 16, 2026 /PRNewswire/ -- Acurx Pharmaceuticals, Inc. (NASDAQ: ACXP) ("Acurx" or the "Company"), a late-stage biopharmaceutical company developing a new class of antibiotics for difficult-to-treat bacterial infections, announced today that the Company will discuss its full year and fourth quarter 2025 financial results on Friday, March 13, 2026 at 8:00 am ET before the U.S. financial markets open. David P. Luci, President and Chief Executive Officer, and Robert G. Shawah, Chief Financial Officer, will host a conference call to discuss the results and provide a business update as follows: Date: Friday, March 13, 2026 Time: 8:00 a.m. ET

0 · Reply

chart_thirst Feb. 15 at 5:45 AM

$ACXP Pre-revenue biotech; clinical-stage pipeline with binary outcomes.

0 · Reply

ChicagoJoe20 Feb. 13 at 2:57 PM

$ACXP you all remember Zinplava? It's a shame that companies discontinue treatments that help yet don't increase EPS. ACXP has a potential silver bullet for C. Diff. What other cures exist?

1 · Reply

Acurx Pharmaceuticals to Discuss Full Year and Fourth Quarter 2025 Financial Results on March 13, 2026 Conference Call and Provide Business Update

Feb 2, 2026, 8:00 AM EST - 21 days ago

USPTO Grants Acurx Pharmaceuticals New Patent for DNA Polymerase IIIC Inhibitors

Nov 18, 2025, 8:00 AM EST - 3 months ago

Health~Holland Awards Another Innovative Research Grant for DNA Pol IIIC Inhibitors to Leiden University Medical Center and Acurx Pharmaceuticals

Nov 12, 2025, 10:11 AM EST - 3 months ago

Acurx Pharmaceuticals, Inc. (ACXP) Q3 2025 Earnings Call Transcript

Nov 12, 2025, 7:01 AM EST - 3 months ago

Acurx Pharmaceuticals, Inc. Reports Third Quarter Results and Provides Business Update

Nov 10, 2025, 8:00 AM EST - 3 months ago

Acurx Announces Publication in the Nature Communications Scientific Journal Documenting its Unique Targeting of DNA pol IIIC Gram-positive Priority Pathogens

Oct 28, 2025, 8:00 AM EDT - 4 months ago

Acurx Announces New Data on its DNA pol IIIC Inhibitor Antibiotics Demonstrating a Potential Class Effect of Gut Microbiome Selectivity Presented at IDWeek 2025 Scientific Conference

Oct 27, 2025, 8:00 AM EDT - 4 months ago

Acurx Pharmaceuticals to Discuss Third Quarter 2025 Financial Results on November 12, 2025 Conference Call and Provide Business Update

Oct 9, 2025, 7:30 AM EDT - 4 months ago

Australian Patent Office Grants Acurx Patent for DNA Polymerase IIIC Inhibitors

Sep 30, 2025, 7:30 AM EDT - 5 months ago

Acurx Announces Positive Opinion from EMA on Pediatric Investigation Plan for Ibezapolstat Use in Children with C. difficile Infection

Sep 3, 2025, 7:01 AM EDT - 6 months ago

Acurx Pharmaceuticals, Inc. Regains Full Compliance with Nasdaq Minimum Closing Bid Price and Stockholder Equity Rules

Aug 12, 2025, 10:13 AM EDT - 6 months ago

Acurx Pharmaceuticals, Inc. (ACXP) Q2 2025 Earnings Call Transcript

Aug 12, 2025, 7:01 AM EDT - 6 months ago

Acurx Pharmaceuticals, Inc. Reports Second Quarter Results and Provides Business Update

Jul 31, 2025, 9:25 AM EDT - 7 months ago

Acurx Pharmaceuticals, Inc. Announces Reverse Stock Split

Jul 24, 2025, 7:01 AM EDT - 7 months ago

Acurx Pharmaceuticals to Discuss Second Quarter 2025 Financial Results on August 12, 2025 Conference Call and Provide Business Update

Jun 17, 2025, 9:47 PM EDT - 8 months ago

Acurx Pharmaceuticals, Inc. Announces Exercise of Warrants for $2.67 Million Gross Proceeds

Jun 17, 2025, 7:01 AM EDT - 8 months ago

Acurx Announces Publication in Lancet Microbe of Phase 2b Clinical Trial Data for Ibezapolstat in CDI

Jun 9, 2025, 7:30 AM EDT - 9 months ago

Acurx Pharmaceuticals Announces Presentation of Results from Leiden University Medical Center Public-Private Partnership for Its DNA pol IIIC Inhibitors at the Federation of American Societies for Experimental Biology Scientific Conference

May 13, 2025, 1:59 PM EDT - 10 months ago

Acurx Pharmaceuticals, Inc. (ACXP) Q1 2025 Earnings Call Transcript

May 13, 2025, 7:01 AM EDT - 10 months ago

Acurx Pharmaceuticals, Inc. Reports First Quarter Results and Provides Business Update

Apr 30, 2025, 7:30 AM EDT - 10 months ago

Acurx Pharmaceuticals to Discuss First Quarter 2025 Financial Results on May 13, 2025 Conference Call and Provide Business Update

Apr 28, 2025, 7:30 AM EDT - 10 months ago

Acurx Pharmaceuticals to Present at the Alliance Global Partners (A.G.P) Healthcare Company Showcase

Apr 17, 2025, 7:30 AM EDT - 11 months ago

Indian Patent Office Grants Acurx Patent for DNA Polymerase IIIC Inhibitors

Mar 18, 2025, 9:44 AM EDT - 1 year ago

Acurx Pharmaceuticals, Inc. (ACXP) Q4 2024 Earnings Call Transcript

Mar 18, 2025, 7:01 AM EDT - 1 year ago

Acurx Pharmaceuticals, Inc. Reports Fourth Quarter and Full Year 2024 Results and Provides Business Update

Mar 10, 2025, 4:30 PM EDT - 1 year ago

Acurx Pharmaceuticals, Inc. Announces Closing of $1.1 Million Registered Direct Offering

Mar 7, 2025, 8:00 AM EST - 1 year ago

Acurx Pharmaceuticals, Inc. Announces $1.1 Million Registered Direct Offering

Mar 3, 2025, 8:00 AM EST - 1 year ago

Acurx Announces Publication of Nonclinical In Vivo Data Differentiating Ibezapolstat's Gut Microbiome Effects from Other Anti-CDI Antibiotics

Feb 28, 2025, 8:00 AM EST - 1 year ago

Acurx Pharmaceuticals to Discuss Fourth Quarter and Full Year 2024 Financial Results on March 18, 2025 Conference Call and Provide Business Update

Feb 24, 2025, 8:00 AM EST - 1 year ago

Acurx Announces Publication of Positive Results from an In-Silico Study Predicting the Microbiome-Restorative Potential of Ibezapolstat in the Treatment of CDI

Feb 19, 2025, 8:00 AM EST - 1 year ago

JPO Grants Acurx Pharmaceuticals Patent in Japan for DNA Polymerase IIIC Inhibitors

Jan 7, 2025, 5:00 PM EST - 1 year ago

Acurx Pharmaceuticals, Inc. Announces Closing of $2.5 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

Jan 6, 2025, 5:35 PM EST - 1 year ago

Acurx Pharmaceuticals, Inc. Announces $2.5 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

Jan 6, 2025, 8:30 AM EST - 1 year ago

Acurx Receives Positive Regulatory Guidance from EMA for Ibezapolstat Phase 3 Program for C. Difficile Infection (CDI)

Dec 11, 2024, 11:00 AM EST - 1 year ago

Acurx Pharmaceuticals to Present at the Microcap Conference, January 28, 2025 - January 30, 2025

Dec 9, 2024, 8:00 AM EST - 1 year ago

Acurx Updates Phase 3 Readiness for Ibezapolstat in C. difficile Infection Based on Recent FDA and EMA Communications

Nov 20, 2024, 10:53 AM EST - 1 year ago

Acurx Pharmaceuticals to add up to $1 million in bitcoin for treasury reserve, following MicroStrategy's playbook

Nov 20, 2024, 7:01 AM EST - 1 year ago

Acurx Board of Directors Approves Bitcoin as Treasury Reserve Asset

Nov 18, 2024, 7:00 AM EST - 1 year ago

Acurx Sponsored and Participated in the Peggy Lillis Foundation Inaugural CDI Scientific Symposium and Presented Ibezapolstat Ph2b Clinical Data Update

Nov 13, 2024, 11:43 AM EST - 1 year ago

Acurx Pharmaceuticals, Inc. (ACXP) Q3 2024 Earnings Call Transcript

Nov 13, 2024, 7:00 AM EST - 1 year ago

Acurx Pharmaceuticals, Inc. Reports Third Quarter 2024 Results and Provides Business Update

Oct 21, 2024, 10:07 AM EDT - 1 year ago

Acurx Ready To Expand Pipeline With Anthrax Treatment

Oct 21, 2024, 7:00 AM EDT - 1 year ago

Acurx Announces New Bile Acid and Microbiome Analyses from Ph2b Trial of Ibezapolstat in CDI Patients Presented at IDWeek Scientific Conference

Oct 17, 2024, 8:00 AM EDT - 1 year ago

Acurx Pharmaceuticals Announces Participation at The Spartan Capital Investor Conference to Showcase Growth Companies and Foster High-Level Investor Engagement

Oct 16, 2024, 8:00 AM EDT - 1 year ago

Acurx Pharmaceuticals to Discuss Third Quarter 2024 Financial Results on November 13, 2024

Oct 14, 2024, 1:00 PM EDT - 1 year ago

New to the Street Resigns Acurx Pharmaceuticals, Inc. to Multi-Platform Media Series Featuring Broadcast Television, Earned Media, and Outdoor Advertising Support

Oct 11, 2024, 10:50 AM EDT - 1 year ago

New to the Street Announces Exclusive Bloomberg Lineup for October 11 at 6:30 PM EST

Sep 26, 2024, 7:00 AM EDT - 1 year ago

Acurx Announces Additional Ibezapolstat Ph2b Results in CDI as well as Anthrax (B. anthracis) Susceptibility to ACX-375 Analogues

Sep 24, 2024, 7:00 AM EDT - 1 year ago

Acurx Announces Results of Its Pioneering Research with Ibezapolstat in Collaboration with Leiden University Medical Center at the Premier International C. difficile Symposium

Aug 26, 2024, 7:00 AM EDT - 1 year ago

ACURX PHARMACEUTICALS ANNOUNCES PARTICIPATION AT THE H.C. Wainwright 26th Annual Global Investment Conference

NotBornYesterday Feb. 23 at 4:07 PM

0 · Reply

PUMPLESTILTSKIN Feb. 21 at 12:07 AM

0 · Reply

AZOZ Feb. 20 at 2:39 PM

$ACXP On watch for possible reversal soon!

2 · Reply

RenDragon Feb. 19 at 6:44 PM

$ACXP so soon we’ll hear from the gravy-man about how the bitcoin investment went.

0 · Reply

RegulatoryPro Feb. 18 at 4:26 PM

$ACXP Acurx Pharmaceuticals focuses on antibiotics with unmet need. Clinical validation is required to unlock valuation. Development timelines are long.

0 · Reply

GoodNewsBull Feb. 18 at 1:43 PM

0 · Reply

Bonso99 Feb. 16 at 5:34 PM

0 · Reply

tomcat79 Feb. 16 at 3:13 PM

0 · Reply

chart_thirst Feb. 15 at 5:45 AM

$ACXP Pre-revenue biotech; clinical-stage pipeline with binary outcomes.

0 · Reply

ChicagoJoe20 Feb. 13 at 2:57 PM

$ACXP you all remember Zinplava? It's a shame that companies discontinue treatments that help yet don't increase EPS. ACXP has a potential silver bullet for C. Diff. What other cures exist?

1 · Reply

OfficialStocktwitsUser Feb. 12 at 5:30 PM

$ACXP RSI: 12.95, MACD: -0.2870 Vol: 0.29, MA20: 2.40, MA50: 2.94 ⚪ HOLD - Sideways 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.

0 · Reply

Bonso99 Feb. 11 at 8:17 AM

$ACXP🫡🫡🫡🫡 https://www.linkedin.com/posts/david-luci-acurx_how-to-rethink-the-fight-against-antimicrobial-activity-7426988631975972864-39wu

0 · Reply

PUMPLESTILTSKIN Feb. 10 at 4:23 PM

$ACXP "We have plenty of cash to finish ph2" -David Luci 2021 Also David Luci: description/date/new shares issued/total shares after/percent dilution Direct Offering /Jul 2022/1,160,000/4,060,000 /40% Direct Offering/May 2023 /600,000/4,660,000/15% ATM Program/2023/700,000 /5,360,000 /15% Direct Offering/Jan 2025 /2,463,058 /7,863,000 /46% Direct Offering/Mar 2025/2,745,000 ~10,608,000 /35% Additional ATM /2024–2025 /20,000,000/30,764,540/189% I believed David Luci for far too long. It is time to not only stop believing him, but to call him out. He is running a scam. Prepare for the next dilution.

2 · Reply

Kastila Feb. 9 at 7:45 PM

$ACXP Buying here this is going to $174. 🚀

3 · Reply

ProTraderColin Feb. 9 at 7:13 PM

$ACXP oh look…they burned shareholders to the ground again. If only someone would have known exactly what was going to happen!

0 · Reply

TWITLIEDETECTOR Feb. 8 at 2:29 AM

$ACXP interesting stock. looking for the bottom

0 · Reply

Jackson1111 Feb. 8 at 12:18 AM

$ACXP So the Pasteur act is being reintroduced in Congress again. It's still alive. This is what Luci has been talking about for years like a savior to the company. Waiting for their view on LinkedIn.

1 · Reply

frbdcsbjax Feb. 6 at 12:52 PM

$ACXP unfortunately, dooms day in very near

0 · Reply

PUMPLESTILTSKIN Feb. 5 at 7:52 PM

$ACXP Dropping about $1 per month, or 50% in 2 months. At this rate they will go under $1 by March-April and do another reverse split. Every month that Luci staves off delistment is another $35K in his pocket in easy salary. He's got every incentive to keep the plate spinning. He's not commercializing a drug, he's commercializing the process of acting like he's commercialize a drug.

2 · Reply

ChicagoJoe20 Feb. 5 at 6:56 PM

$ACXP did they end up creating a BTC reserve? 😶

0 · Reply

MarketForecasting Feb. 5 at 3:26 PM

$ACXP pigs at the trough with this company , stay away . Collected millions in pre ipo holders and post ipo holders money with absolutely nothing to show for . Nothing but a 20 person trial and a reverse split . Good thing is filing a lawsuit against them personally for misleading statements is a lot easier given the size of the 4 stooges operation.

0 · Reply

xolli Feb. 5 at 3:08 PM

$ACXP scam... Huge scam

0 · Reply

Market Cap	4.23M
Revenue (ttm)	0.00
Net Income (ttm)	-14.10M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	0.00

Volume	205,884
Avg Vol	48,298
Day's Range	N/A - N/A
Shares Out	2.55M
Stochastic %K	0%
Beta	-1.22
Analysts	Strong Sell
Price Target	$27.00